According to an article published by the NIH in October 2021, between 10 & 20% of all NAFLD diagnosed individuals are lean, with an estimated US population between 8 & 10 million. Virtually all of those "lean" patients will graduate to NASH. If we assume the lower number, 8 million, and also peg Resmetirom at $30k per year, we get a potential market of $24 billion, most of which Madrigal can capture with a 3-4 year head start.